| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Endocrine, Metabolic, and Digestive Diseases, and Diagnostic Imaging Department (R.F., C.M.P.), Ospedale Regina Apostolorum, Albano; Systematic Medical Therapy Institute, Umberto I Polyclinic (V.B.); and the Department of Experimental Medicine, La Sapienza University (F.N.), Rome, Italy
Address all correspondence and requests for reprints to: Dr. Enrico Papini, Department of Endocrine, Metabolic, and Digestive Diseases, Ospedale Regina Apostolorum, Via San Francesco 50, 00041 Albano, Rome, Italy.
We studied for 5 yr a homogeneous group of 83 patients randomly assigned to a levothyroxine (L-T4) suppressive therapy or to a control group to evaluate changes in nodule or thyroid size, appearance of new nodules, and correlations with clinical parameters.
In the control group, mean nodule volume increased significantly after 5 yr (2.12 ± 1.46 vs. 1.46 ± 0.77 mL), whereas in the treatment group it decreased, although not significantly (1.45 ± 1.17 mL vs. 1.53 ± 0.61 mL). Baseline nodule volume was not different in the two groups, but a significant difference was observed at 5 yr. After 5 yr, sonograms detected 12 new nodules in the control group (28.5%) and 3 (7.5%) in the treatment group. Nodule shrinkage was more frequent in patients with complete TSH suppression, but no correlation was found with other parameters. A significant increase in thyroid size was observed in the control group.
In conclusion, long term TSH suppression induced volume reduction in only a subgroup of thyroid nodules, but effectively prevented the appearance of new lesions and increases in nodule and thyroid volume. As the changes in the natural history of nodular goiter are related to prolonged TSH suppression, which can induce unfavorable side-effects, L-T4 suppressive therapy should be reserved for small nodules in younger patients.
This article has been cited by other articles:
 |
|
 |
|
  M. R. Haymart, D. J. Repplinger, G. E. Leverson, D. F. Elson, R. S. Sippel, J. C. Jaume, and H. Chen Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor Stage J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 809 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Ross Predicting thyroid malignancy. J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4253 - 4255. [Full Text] [PDF]
|
|
|
|
|
|
K. Krohn, D. Fuhrer, Y. Bayer, M. Eszlinger, V. Brauer, S. Neumann, and R. Paschke Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter Endocr. Rev., June 1, 2005; 26(4): 504 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Mandel A 64-Year-Old Woman With a Thyroid Nodule JAMA, December 1, 2004; 292(21): 2632 - 2642. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hegedus The Thyroid Nodule N. Engl. J. Med., October 21, 2004; 351(17): 1764 - 1771. [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Alexander, S. Hurwitz, J. P. Heering, C. B. Benson, M. C. Frates, P. M. Doubilet, E. S. Cibas, P R. Larsen, and E. Marqusee Natural History of Benign Solid and Cystic Thyroid Nodules Ann Intern Med, February 18, 2003; 138(4): 315 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Wemeau, P. Caron, C. Schvartz, J.-L. Schlienger, J. Orgiazzi, C. Cousty, and V. Vlaeminck-Guillem Effects of Thyroid-Stimulating Hormone Suppression with Levothyroxine in Reducing the Volume of Solitary Thyroid Nodules and Improving Extranodular Nonpalpable Changes: A Randomized, Double-Blind, Placebo-Controlled Trial by the French Thyroid Research Group J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4928 - 4934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Castro, P. J. Caraballo, and J. C. Morris Effectiveness of Thyroid Hormone Suppressive Therapy in Benign Solitary Thyroid Nodules: A Meta-Analysis J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4154 - 4159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Samuels Editorial: Evaluation and Treatment of Sporadic Nontoxic Goiter--Some Answers and More Questions J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 994 - 997. [Full Text]
|
|
|
|
|
|
Changes in Thyroid Nodule Volume Caused by Fine-Needle Aspiration: A Factor Complicating the Interpretation of the Effect of Thyrotropin Suppression on Nodule Size J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4566 - 4569. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hegedüs, B. Nygaard, and J. M. Hansen Is Routine Thyroxine Treatment to Hinder Postoperative Recurrence of Nontoxic Goiter Justified? J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 756 - 760. [Abstract] [Full Text]
|
|
|
|
|
|
F. Zelmanovitz, S. Genro, and J. L. Gross Suppressive Therapy with Levothyroxine for Solitary Thyroid Nodules: A Double-blind Controlled Clinical Study and Cumulative Meta-analyses J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3881 - 3885. [Abstract] [Full Text]
|
|
|
|
 |
|
 Suppressive Therapy for Cold Thyroid Nodules: Not for Everyone Journal Watch Women's Health, April 1, 1998; 1998(401): 20 - 20. [Full Text]
|
|
|
|
 |
|
 Approaches to Solitary Thyroid Nodules Journal Watch (General), March 24, 1998; 1998(324): 3 - 3. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
